Bispecific Therapies in RRMM: Teclistamab, Talquetamab, and Elranatamab Updates
Insight into the latest updates on three approved bispecific therapies in the context of relapsed and refractory multiple myeloma, including teclistamab, talquetamab, and elranatamab, discussing response rates, administration, and side effects.
Video Player is loading.
EP: 1.Evolving Treatment Paradigms in Relapsed/Refractory Multiple Myeloma
EP: 2.Earlier Use of Novel Therapeutics in Multiple Myeloma Treatment Pathways
EP: 3.Patient Scenario: Management of Multiple Myeloma With Talquetamab Therapy
Now Viewing
EP: 4.Bispecific Therapies in RRMM: Teclistamab, Talquetamab, and Elranatamab Updates
EP: 5.Bispecific Therapies in Multiple Myeloma: Impact on Real-World Practice
EP: 6.Adverse Events With Bispecific Therapy: Dysgeusia, Skin, and Nail Changes
EP: 7.Managing AEs in Multiple Myeloma: Dosing and Prophylactic Strategies
EP: 8.Multiple Myeloma: Optimizing ICANS and CRS Management
EP: 9.Managing Toxicity Following Bispecific Therapy in R/R Multiple Myeloma
EP: 10.Patient Scenario: Navigating Sequencing in Multiple Myeloma
EP: 11.CAR-T vs BCMA Bispecifics: Navigating Myeloma Treatment Decisions
EP: 12.Navigating CAR-T Therapy in RRMM: Patient Counsel and Managing AEs
EP: 13.Advancements in Multiple Myeloma IO Therapy: Key Takeaways
Recent Videos
Managing Epithelioid Sarcoma: Follow-Up Strategies and Treatment Decisions for Stable Disease vs Progression
Navigating Frontline Therapy in Epithelioid Sarcoma: Key Clinical Considerations and Shared Decision-Making
Optimizing Multidisciplinary Coordination for Successful Tarlatamab Implementation
Institutional Implementation: Setting Up Tarlatamab Administration
Choosing Between Tazemetostat and Zanubrutinib+Obinutuzumab: Key Factors & Patient Conversations
Expert Perspectives: Tazemetostat in R/R FL
Management Strategies for Localized Epithelioid Sarcoma: The Role of Neoadjuvant and Adjuvant Therapies
Key Takeaways and Future Perspectives: PSMA PET Imaging in Prostate Cancer
Evaluating the Role of Cu-PSMA PET Imaging in Prostate Cancer
A 62-Year-Old Woman With Epithelioid Sarcoma Treated With Tazemetostat
Related Content
!["[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fb319d51b3dcc8ae143eae44a72a0aff757b330db-800x533.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation,\" according to the study authors.")
![“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F4de1e119837b011168a7884a19a600b14bb6a258-3600x2400.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.")
